In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
about
Bisphosphonates in multiple myeloma: a network meta-analysisBisphosphonates in multiple myelomaA role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasionActions of bisphosphonates in animal models of breast cancerDiagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvementNanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxelPamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancerButyrate induces profound changes in gene expression related to multiple signal pathways in bovine kidney epithelial cells.Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.Anti-tumour activity of bisphosphonates in human myeloma cells.Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG).Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma.Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies.In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease.Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cellsThe potential role of bisphosphonates in prostate cancer.The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells.Bisphosphonate therapy in the oncology setting.Advances in the use of bisphosphonates in the prostate cancer setting.Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells.Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity.Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibodyZoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.Antiangiogenic effects of zoledronate on cancer neovasculature.Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines.Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in human follicular lymphoma cells.Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines.Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation.A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells.The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro.
P2860
Q24197839-C95EF2C4-2772-4775-9643-35DE96CAE1BBQ24236776-95A7CBB7-7E1D-4185-9BFA-2039C0ABE477Q24301997-DFEBE0F9-2D2A-445B-9012-3713A14F844CQ24802119-CAAC96EB-653A-4A57-A006-7F6821ABD587Q27011865-1761232E-DC07-442D-9A5D-74C4438884E4Q27302083-EA806E91-539D-4051-A58D-A9D383C7F4E5Q28362972-1072D228-B319-40A7-9C46-E713A74589BAQ28366607-4277E312-DC3D-4236-9DCB-3481C7CA55ADQ33257585-C0E33F7C-97CB-445C-AE9F-9FBB2D18BC91Q33269187-CB5AF055-0ED3-44BD-9A72-DD2B04896240Q33536291-1FAF3B4F-4E7A-43DB-85A8-E15D233991A9Q33898576-2A013A83-5FEF-4B20-9BB4-DA424DA69A9DQ33970512-4D387B16-986B-4F6B-94F7-6A4E02E84785Q33970595-EC3224EE-85C3-4B36-9B4A-DD3C06D5F21EQ34427554-436CE709-AC77-449C-AA7C-36FFD9680C38Q35043887-A3D10120-323E-44F3-83C3-1012F339FF29Q35081743-2A749C8C-B236-43ED-A795-DAE21A149DCFQ35584866-206D3383-6EE9-4983-AF4D-0599563FF5D1Q35590612-480DB18F-B0FC-43AB-AF6E-DFE78A3B8777Q35602668-971C096D-535C-4E23-B8A4-4BA5CBB973A4Q35679766-41158732-EA94-48A8-8016-ADFA9ABE0DC1Q36194583-6EC7DD4E-1A05-4BD1-9512-D60D1DCE7196Q36217148-10E1ADD9-B14C-4D7E-8EA2-E5C30226FF33Q36644394-FF01ECC5-5D89-4797-B0BC-6E9B5DD2B48FQ36810618-9B28BC13-F721-4D74-9963-B5A65434363CQ36871994-F6944401-F12C-423F-95C2-95E1FE2C23ADQ37278425-BD4A8541-9C44-4054-B783-EE938EB3F8EAQ37340505-7761868F-A041-498D-A18B-CDD39F318CC4Q37493951-ABE19089-1455-446C-9276-22E480E24C62Q37694808-B9E76FF2-E6EB-4B2C-BB03-3C79F6CAF8F3Q37951606-D91E9165-9B24-4942-AB96-FC7C95471CE4Q38867820-274669CC-04D4-42E1-9A20-A3B8B7FBB544Q39709311-E273F85A-99A6-4DDC-B861-9A86290781E2Q39781826-2F4C6AFA-6174-4CD8-9A86-1A15679FBF4DQ39902586-5B58E9C4-09FB-442E-B620-28F6D1D83810Q40373041-25DD3E6B-C78B-4E7D-99ED-23FA362730F1Q40541785-29CB2FF0-A1F0-4A95-8889-F64ABF766818Q40609773-25893FDB-09D5-41CA-A08C-69EBEB30C777Q41988099-F07B4570-F9D2-4BA9-890C-440F2E2517C6Q41989625-CBDB874E-84FF-4DE9-A4C4-3205E510E55C
P2860
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
@en
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
@nl
type
label
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
@en
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
@nl
prefLabel
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
@en
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
@nl
P2093
P356
P1433
P1476
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
@en
P2093
P2888
P304
P356
10.1038/SJ.LEU.2400892
P577
1998-02-01T00:00:00Z